Abstract 166P
Background
Schwann cells (SCs) are a type of peripheral nerve system(PNS) glial cell that support the viability of myelinated and unmyelinated peripheral nerve fibers. Our previous studies identified SCs in human lung cancer specimens and demonstrated that SCs could increase the metastasis of lung cancer by activating the PI3K/AKT/GSK-3b/Snail-7wist signaling pathway and enhancing M2 macrophage polarization via CCL2 secretion. However, in the lung cancer mouse model, complete identification of airway nerves (or other cellular/subcellular objects) has not been possible due to patchy distribution and micron-scale size.
Methods
In this study, we describe a method using tissue clearing to acquire the first complete image of three-dimensional (3D) innervation in lung cancer. Mouse airways were harvested from the Metastatic tumor model of C57BI/6 mice and separated from the heart. The tissues were dehydrated, rehydrated and completely transparented. The specimens were labeled for the pan-neuronal marker PGP9.5 with a mouse antibody. All images were acquired using a confocal microscope. 3D images of fluorescently casted airways were processed to make airway masks. To quantify visceral pleural nerve distribution in mice, nerves were modeled using computer tractography and measured in different lung cancer regions.
Results
We found that nerves are widely distributed in both lung and lung tissues. The shape of peripheral nerves is similar to blood vessels, showing reticular shape along the bronchi and bronchioles. However, the distribution of peripheral nerves in the lung has not changed due to lung cancer. Interestingly and critically, the fluorescence intensity of the nerve near the side of lung cancer is much stronger, suggesting that the phenotype of peripheral nerves may change after interaction with lung cancer cells. The nerve growth in lung cancer tissue is abundant and active.
Conclusions
We first complete the image of three-dimensional (3D) innervation in lung cancer. The interaction between peripheral nerves and lung cancer may affect the phenotype of peripheral nerves and thus regulate the malignant biological course of lung cancer. PNS may play an oncogenic role in lung tumor progression and may serve as a therapeutic target for further analysis.
Legal entity responsible for the study
Shanghai Chest Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display